ClinicalTrials.gg
Not yet recruitingNCT06663189TWINSUpdated Jan 3, 2025

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

A Phase 3 interventional study of treatment withdrawal and Usual DMT continuation in Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by University Hospital, Strasbourg, France. Not yet recruiting at 22 sites in France. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by University Hospital, Strasbourg, France · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.

Planned enrollment
30th of 70
200 · median 154
Started
2025
with 3 others
Phase 3
33 of 82
3 open now
Primary completion
2027-01
later than 4 of 13 live
Registered
76th of 82
by date
Lead sponsor
4 of 82
University Hospital, Strasbourg, France

Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 30th largest by planned enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2025, is one of 33 in phase 3, reaches primary completion later than 4 of the 13 other live ones, and was the 76th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage. It is the most common cause of neurological disability in young adults, involving a long-term therapeutic follow-up. 85% of the patients are diagnosed with Relapsing-Remitting form of MS (RRMS). This form is characterized by clearly defined acute or subacute neurological symptoms (relapses) followed by periods of partial to complete recovery.

Disease-modifying therapies (DMT) used to treat RRMS are immunomodulatory or suppressor molecules which have proven efficacy in limiting disease activity (decreasing relapse rate and delaying time to disease progression).

However, the long-term safety of DMT is uncertain, as there is an increased risk of developing adverse events or infections (sometimes severe) such as observed in the last pandemic of COVID-19 (higher risk of infection), highlighting the need to reassess the benefit/risk ratio of maintaining immunomodulatory or suppressive therapy in the MS population. In elderly patients with comorbidity, this risk is further increased. To date, few studies on the discontinuation of treatment in elderly RRMS patients have been conducted. However, those available demonstrate that there was no difference in relapse rates between patients who continued or discontinued treatment. These results are consistent with immunosenescence studies in RRMS that suggested a negative correlation between relapse rate/inflammatory processes and age. On the contrary, there is evidence indicating a positive correlation between age and the number of infections.

In addition, in the current context in France, it is important to take into account the medico-social cost associated with long-term treatments. In France, the average estimated annual cost per patient is 12,000€, more than half of which is attributed to medications.Furthermore, with age progression, an inversion of the benefit/cost assessment has been observed in treated patients.

Considering these medical and medico-social factors, it is reasonable to question the value of continuing treatment in stable patients with RRMS over 55 years.

This is a randomized, controlled, multicentric, open-label, parallel groups, 1:1 ratio non-inferiority clinical trial, comparing (1) a group that will stop treatment, to (2) a group that will continue treatment, over the course of 2 years, to determine the survival rate without MS activity defined clinically or by imaging.

The patients in both arms will be followed over 2 years after randomization. 5 visits will be performed for all patients: inclusion/randomization visit (M0) and 4 follow-up visits every 6 months (M6, M12, M18, and M24). An additional phone call at M3 is planned.

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis (RRMS)
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient (male or female) aged 55 and over
  2. RRMS diagnosis according to revised McDonald 2017 criteria
  3. First MS symptom >5 years ago. If the date is unknown, RRMS diagnosis >5 years ago
  4. Stable disease in the last 5 years according to the revised Lublin and Reingold classification characterized by :

    Stable T2 lesions documented by MRI performed at least 5 years prior to inclusion versus MRI performed within 6 months prior to the inclusion visit, AND Stable EDSS documented at least 5 years prior to inclusion versus EDSS documented within 6 months prior to inclusion visit, according to the investigator's judgment, AND The absence of relapses within 5 years prior to the inclusion visit

  5. Treated with a Moderate Efficacy Therapy (MET) for at least 5 consecutive years (IFN-β, glatiramer acetate, dimethyl fumarate, teriflunomide, diroximel fumarate); switching from one treatment to another is accepted if the reason for the change is related to personal convenience or intolerance to the first treatment.
  6. Patient with affiliation to a social security regimen
  7. Patient able to understand the objectives and risks associated with the research and to give to the study
  8. Patient willing and able to comply with study procedures for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Primary progressive or secondary progressive with or without relapse as defined by the revised Lublin and Reingold classification
  2. Previous or ongoing treatment with a High Efficacy therapy (HET), with the exception of induction therapy (mitoxantrone, stem cell transplantation, alemtuzumab) provided that the last administration took place at least 10 years prior to inclusion.
  3. to MRI (claustrophobia, weight ≥ 140 kg, pacemaker, cochlear implants, foreign body in eye, intracranial vascular clips, surgery in the 6 weeks prior to the beginning of the study, coronary stent implanted in the 8 weeks prior to the beginning of the study,...).

    NB : Gadolinium contraindication will not prevent recruitment of the patient; in this case MRI will be carried out without contrast product injection

  4. History of neurological disease affecting the central nervous system: hereditary degenerative CNS disease, degenerative cognitive disease, systemic disease, sarcoidosis, Lyme disease...
  5. Chronic disease which requires chronic treatment with corticoids or immunosuppressors
  6. Uncontrolled cardiac, renal or hepatic disease
  7. Patient participating in another interventional trial (drug or a medical device) or patient who are still within an exclusion period
  8. Patient wishing to discontinue background therapy, whether or not they are experiencing adverse effects.
  9. Patient not considering discontinuing background therapy, whether or not they are experiencing adverse effects.
  10. Pregnant or breastfeeding woman
  11. Patient with difficulty to read or understand French,
  12. Patient subject to a legal protection measure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Experimental

    Treatment withdrawal; patients will stop their Disease Modifying Treatment (DMT)

    Drug: treatment withdrawal · Other: MRI · Behavioral: Quality of Life questionnaires · Other: Disability evaluation tests

  • Active comparator
    Control arm

    Patients will continue their DMT as per routine pratice

    Drug: Usual DMT continuation · Other: MRI · Behavioral: Quality of Life questionnaires · Other: Disability evaluation tests

Interventions

  • Drugtreatment withdrawal

    Patients will STOP their DMT

  • DrugUsual DMT continuation

    Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate

  • OtherMRI

    Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit

  • BehavioralQuality of Life questionnaires

    EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire

  • OtherDisability evaluation tests

    EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test

06

What researchers measure

Primary outcomes

  1. Time to first clinical and/or radiological disease activity during a period of 2 years.

    A clinical activity (relapse) is defined by the occurrence of new or worsening of neurological symptoms linked to MS. Relapses must meet the following criteria: * Symptoms must last at least 24 hours, without other clinical factors leading to confusion (fever, infection, lesion, drug adverse events) * Must be followed by improvement or resolution of the neurological state within 30 days * New symptoms or worsening of neurological state must be accompanied by an objective neurologic state aggravation * The neurological symptom must be linked to the modified FSS (pyramidal, cerebellar, brainstem, sphincter, mental, sensory or visual functions) A radiological activity is defined if MRI shows either: * at least 3 new or enlarged T2 ≥ 3 mm on the same exam or * at least 3 cumulative new or enlarged T2 lesions ≥ 3 mm during follow up or * one enhanced gadolinium lesion compared to the previous MRI.

    Time frame: From enrollment to the end of study visit at 24 months

07

Study locations

22 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jan 2027, 24 months later.

Of 38 phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 66. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 29, 2024
StartEst.
Jan 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2029
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06663189
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Oct 29, 2024
Start date
Jan 2025 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
Jan 3, 2025

Study contacts

Sarah HUSTACHE
Contact
dpidrci@chru-strasbourg.fr
03 3 88 11 54 15 ext. 00 33
Nicolas COLLONGUES, MD, PhD
principal investigator · University Hospital, Strasbourg, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion